How should autoimmune encephalitis with a temporal lobe lesion be treated, specifically regarding intravenous immunoglobulin (IVIG) therapy?

Treatment of Autoimmune Encephalitis with Temporal Lobe Lesion

For autoimmune encephalitis with temporal lobe involvement, initiate high-dose intravenous methylprednisolone immediately after excluding infection, and add IVIG or plasma exchange if there is no improvement after initial steroid therapy or if steroids are contraindicated. 1

First-Line Treatment Approach

Immediate Steroid Therapy

• Start high-dose intravenous methylprednisolone as soon as basic CSF analysis excludes infection, without waiting for complete antibody results 1
• This represents the standard first-line approach for autoimmune encephalitis regardless of temporal lobe involvement 1

When to Use IVIG as First-Line Instead of Steroids

IVIG should be used as an alternative first-line agent when steroids are contraindicated 1:

• Uncontrolled hypertension 1
• Uncontrolled diabetes 1
• Active peptic ulcer disease 1
• Severe behavioral symptoms that worsen with corticosteroids 1

IVIG Efficacy Evidence

• Prospective trial data demonstrates IVIG (0.4 g/kg/day for 5 days) produces significant improvement in modified Rankin Scale scores by day 8 2
• In severe anti-NMDAR encephalitis, IVIG shows effectiveness with 50% of patients achieving clinical improvement at 30 days 3
• Retrospective data from 388 patients shows no significant outcome difference between methylprednisolone plus IVIG versus methylprednisolone plus plasma exchange across NMDAR, LGI1, and CASPR2 antibody subtypes 4

Escalation Strategy for Non-Responders

Adding IVIG or Plasma Exchange

If no clinical improvement occurs after initial first-line therapy, add IVIG or plasma exchange 1:

Choose IVIG preferentially when:

• Patient is agitated or combative 1
• Bleeding disorders are present 1
• Vascular access for plasma exchange is problematic 1

Choose plasma exchange preferentially when:

• Severe hyponatremia is present 1
• High thromboembolic risk exists (known/suspected cancer, smoking, hypertension, diabetes, hyperlipidemia) 1
• Concurrent demyelinating disease 1

Plasma Exchange Specifications

• Administer 5-10 sessions every other day 1
• Recent data suggests plasma exchange may produce slightly faster antibody clearance and earlier clinical improvement in severe NMDAR encephalitis compared to IVIG, though long-term outcomes are equivalent 3

Severe Presentations Requiring Upfront Combination

For severe NMDAR-antibody encephalitis, new-onset refractory status epilepticus (NORSE), or fulminant presentations, initiate combination therapy (steroids + IVIG or steroids + plasma exchange) from the outset rather than sequentially 1

This aggressive approach is critical because:

• Temporal lobe involvement often indicates more severe disease 1
• Delayed treatment escalation worsens outcomes 1
• Combination therapy from the start prevents clinical deterioration 1

Second-Line Immunotherapy (2-4 Weeks Post-Failure)

For antibody-mediated autoimmunity targeting surface antigens (NMDAR, LGI1, CASPR2), rituximab is the recommended second-line agent 1

For classical paraneoplastic syndromes with intracellular antibodies, cyclophosphamide should be initiated 1

Critical Safety Monitoring with IVIG

Renal Function

• Ensure patients are not volume-depleted before IVIG administration 5
• Monitor BUN and serum creatinine before infusion and at appropriate intervals 5
• Use minimum dose and infusion rate in patients with pre-existing renal insufficiency, diabetes, age >65, volume depletion, or sepsis 5

Thrombosis Risk

• Ensure adequate hydration before administration 5
• Monitor for thrombosis signs/symptoms, particularly in patients with advanced age, immobilization, hypercoagulable conditions, or cardiovascular risk factors 5
• Consider baseline blood viscosity assessment in high-risk patients 5

Infusion Protocol

• Start at 0.01 mL/kg/min (0.5 mg/kg/min) 5
• If tolerated after 30 minutes, gradually increase to maximum 0.10 mL/kg/min (5 mg/kg/min) 5
• Slow or stop if adverse reactions occur 5

Common Pitfalls to Avoid

• Do not delay immunotherapy waiting for antibody results—temporal lobe lesions on MRI with clinical encephalitis warrant immediate treatment after infection exclusion 1
• Do not use IVIG monotherapy when combination therapy is indicated for severe presentations—this delays recovery and worsens outcomes 1
• Do not continue ineffective first-line therapy beyond initial assessment period—escalate to IVIG/plasma exchange or second-line agents at 2-4 weeks if no response 1
• Avoid volume depletion before IVIG—this significantly increases renal failure and thrombosis risk 5